Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 16, Issue 5, Pages 543-556Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.2016.1168697
Keywords
Chemotherapy; surgery; different patterns of disease; survival; multidisciplinary; genomic complexity; tailored therapy; targeted drugs
Categories
Ask authors/readers for more resources
Osteosarcoma is the most common malignant bone tumor, currently treated with pre-and postoperative chemotherapy in association with the surgical removal of the tumor. About 15-20% of patients have evidence of metastases at diagnosis, mostly in the lungs. Patients with metastatic disease still have a very poor prognosis, with approximately 20-30% of long-term survivors, as compared with 65-70% of patients with localized disease. The optimum management of these patients has not been standardized yet due to several patterns of metastatic disease harboring different prognosis. Complete surgical resection of all sites of disease is mandatory and predictive of survival. Patients with multiple sites of disease not amenable to complete surgery removal should be considered for innovative therapeutic approaches because of poor prognosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available